Saturday 17 October 2026
Export ONCO’s income statement to Excel — free account
Onconetix, Inc.
ONCO Healthcare Biotechnology
Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024. In the quarter to June 2026, revenue fell 83.9%, EPS grew 99.5% and free cash flow fell 36.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.48
0.07
−12.73%
Follow ONCO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 154,700.00 | 27,200.00 | 1,343.00 | 68.50 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 15,453,000.00 | 331,500.00 | 90,950.00 | 4,420.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 5 | 12 | 12 | 7 | 8 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.36 | 0.10 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 3 | 1 | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (1,926.84) | 41.80 | 77.62 | |||||
| EBT | — | — | — | (1) | (2) | (3) | (13) | (37) | (60) | (14) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (63,969.74) | (2,366.63) | (1,720.85) | |||||
| Net income | — | 0 | — | (1) | (2) | (3) | (13) | (37) | (59) | (14) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 1 | 12 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 585.00 | 4,206.83 | 43.37 | ||||
| Earnings | — | — | — | (0.10) | (0.50) | (1.07) | (1.09) | (371,186.40) | (90,889.84) | (828.00) | |||||
| Cash flow | — | — | — | (0.07) | (0.54) | (0.64) | (0.71) | (135,810.00) | (17,493.00) | (514.81) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (61,348.00) | (47.50) | 0.00 | |||||
| Free cash flow | — | — | — | (0.07) | (0.54) | (0.64) | (0.71) | (197,158.00) | (17,540.50) | (514.81) | |||||
| Book value | — | — | — | 0.54 | 1.48 | 0.45 | 1.82 | 14,045.00 | 14,237.67 | 838.54 | |||||
| Shares, m | — | — | — | 11 | 3 | 3 | 12 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.64 | 1.80 | |||||
| P/B | — | — | — | — | — | — | — | 2.36 | 0.19 | 0.09 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.43 | (4.46) | |||||
| EV/FCF | — | — | — | — | — | — | — | 0.06 | (0.10) | 0.37 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (2) | (2) | (9) | (14) | (10) | (10) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | (6) | 0 | — | |||||
| Free cash flow | — | — | — | (1) | (2) | (2) | (9) | (20) | (11) | (10) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 6 | 5 | 1 | 22 | (11) | (17) | (3) | ||||
| Total debt | — | — | — | — | — | — | — | 0 | — | — | |||||
| Net debt | — | — | — | (6) | (4) | (2) | (26) | (4) | (1) | (5) | |||||
| Shareholders’ equity | — | — | — | 6 | 5 | 1 | 22 | 1 | 9 | 16 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (36.24) | (39.65) | (102.44) | (91.96) | (65.73) | (101.81) | (58.49) | ||||
| ROIC | — | — | — | 0.00 | (238.54) | 0.00 | 0.00 | 0.00 | (447.13) | (105.85) | |||||
| ROE | — | — | — | (20.53) | (40.24) | (130.89) | (113.42) | (314.47) | (1,184.21) | (127.79) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Onconetix, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ARAV ARAVIVE, INC | $3.0M | — (loss-making) | — (loss-making) | −44.39% (below 0%: shrinking) | n/m | +48.19% (above 0%: growing) | 100.00% | (323.44%) | Compare |
| DCOY Decoy Therapeutics Inc | $2.9M | 0.0× | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| MBIO Mustang Bio, Inc. | $2.9M | — (loss-making) | — | — | n/m | +27.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BCAB BioAtla, Inc. | $2.9M | — (loss-making) | — (loss-making) | +4,233.33% (above 0%: growing) | n/m | +97.03% (above 0%: growing) | 100.00% | 3.49% | Compare |
| ONCO Onconetix, Inc. | $2.9M | 0.0× | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | |
| VIVS VivoSim Labs, Inc. | $2.8M | — (loss-making) | — (loss-making) | −51.35% (below 0%: shrinking) | n/m | +17.87% (above 0%: growing) | 100.00% | (15,327.78%) | Compare |
| AFMDQ Affimed N.V. | $2.8M | — (loss-making) | — (loss-making) | −92.02% (below 0%: shrinking) | n/m | +46.95% (above 0%: growing) | 100.00% | (9,216.90%) | Compare |
| HCWB HCW Biologics Inc. | $2.8M | — (loss-making) | — (loss-making) | +1,954.55% (above 0%: growing) | n/m | −20.84% (below 0%: shrinking) | (69.25%) | (2,335.03%) | Compare |
| SLXN Silexion Therapeutics Corp | $2.7M | — (loss-making) | — | — | n/m | −16.63% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $2.9M | — | — | −47.87% | — | +22.83% | 100.00% | (689.71%) |
Onconetix, Inc. (ONCO) key facts
- Concern: Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024.
- Onconetix, Inc. (ONCO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ONCO traded at $0.48, a market capitalization of $2.9 million.
- Return on equity was −127.8% and debt-to-equity 0.00.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −9.75 (distress zone) for fiscal 2025.